Rebiotix Wins 2013 Leaders in Health Care Award
Download this press release (334 KB).
ROSEVILLE, Minn. (October 31, 2013) — Rebiotix Inc. has been named winner of the Startup category in the 2013 Leaders in Health Care Award competition sponsored by Minnesota Business Magazine. The award recognizes a remarkable new health care company established in Minnesota within the past three years.
The goal of Rebiotix, a clinical-stage biotechnology company, is to revolutionize the treatment of patients suffering from debilitating gastrointestinal diseases. Led by seasoned industry veterans, the company has gone from concept to clinical application in less than two years utilizing one of today’s most promising areas of medical innovation: the human microbiome.
The company’s product platform is based on the transplantation of live human-derived microbes into the intestinal track of sick patients to alleviate their disease. RBX2660, the company’s first product, is targeted at the treatment of patients who are suffering from repeated episodes of Clostridium difficile infection (CDI). It is first in a new class of drugs to address this patient population. Rebiotix received Investigational New Drug approval from the FDA in July; its Phase 2 trial is underway.
“We are honored to be recognized as a leader in Minnesota’s innovative health care community by Minnesota Business Magazine for the progress we’ve made pioneering this new therapy to treat life-threatening disease,” said Rebiotix CEO Lee Jones.
CDI has become one of the most common health care-associated infections in the U.S., affecting more than 700,000 patients annually and linked to more than 14,000 deaths each year. Approximately 20 to 30 percent of patients with CDI who are treated with commonly used first-line antibiotics experience a recurrence. The risk of recurrence increases with each relapse or reinfection. Currently, the only treatments available for patients with recurrent disease are more antibiotics or surgery, both of which have serious limitations.
Rebiotix Inc. is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases, such as recurring Clostridium difficileinfection, by harnessing the power of the human microbiome. The Roseville, Minn.-based company is pioneering practical and non-antibiotic treatments that reverse pathogenic processes and restore healthy gut flora through the transplantation of live microorganisms. For more information, visit www.Rebiotix.com.